Trastuzumab deruxtecan kills skin and uveal melanoma in vivo by HER2-independent payload release
Lisa M. Nilsson, Elif Sila Tanaydin, Sofia Stenqvist, David Jansson, Lars Ny, Jonas A. Nilsson
This study shows trastuzumab deruxtecan (T-DXd) effectively kills melanoma in vivo, even when HER2 is not expressed, due to extracellular cathepsin L-mediated payload release.
bioRxiv · Oct 12, 2026 · PreprintCancer Biology